布鲁顿酪氨酸激酶抑制剂联合方案在弥漫大B细胞淋巴瘤治疗中的研究进展  

Progress of Bruton tyrosine kinase inhibitor combined regimens in treatment of diffuse large B-cell lymphoma

作　　者：张婉婉 任崇崇 吴庭恺 刘蓓[2] Zhang Wanwan;Ren Chongchong;Wu Tingkai;Liu Bei(The First Clinical Medical College of Lanzhou University,Lanzhou 730030,China;Department of Hematology,the First Hospital of Lanzhou University,Lanzhou 730030,China)

机构地区：[1]兰州大学第一临床医学院,兰州730030 [2]兰州大学第一医院血液内科,兰州730030

出　　处：《白血病．淋巴瘤》2024年第8期505-509,共5页Journal of Leukemia & Lymphoma

摘　　要：弥漫大B细胞淋巴瘤(DLBCL)可由病毒和自身免疫功能等多重因素引起, 继而引发B细胞受体(BCR)信号通路及其他相关信号通路的持续性激活, 共同促进B细胞恶性增殖, 导致肿瘤生成。研究显示在布鲁顿酪氨酸激酶抑制剂(BTKi)单药治疗不佳的情况下, BTKi联合化疗、免疫制剂和小分子抑制剂治疗初治、复发难治DLBCL取得显著进展。文章就BTKi联合方案在DLBCL中的研究进展作一综述。Diffuse large B-cell lymphoma(DLBCL)can be caused by multiple factors,including virus and autoimmune function,which in turn trigger persistent activation of the B-cell receptor(BCR)signaling pathway and other related signaling pathways,which collectively promote malignant B-cell proliferation and lead to tumor formation.Studies have shown significant progress in the treatment of primary and relapsed/refractory DLBCL with Bruton tyrosine kinase inhibitor(BTKi)in combination with chemotherapy,immunotherapy and small molecule inhibitors in the setting of poor outcome with BTKi monotherapy.This article reviews the progress of BTKi combined regimens in DLBCL.

关 键 词：淋巴瘤 大B细胞 弥漫性 蛋白激酶抑制剂 抗肿瘤联合化疗方案 布鲁顿酪氨酸激酶 

分 类 号：R733.1[医药卫生—肿瘤]